Індукована хіміотерапією аменорея у хворих на рак молочної залози: основні механізми та діагностичні критерії порушення функції яєчників

І. Б. Щепотін, О. С. Зотов, М. Ф. Анікусько, І. І. Любота, Р. В. Любота


Occurrence of amenorrhea during chemotherapy in patients with breast cancer, some authors regard as a method of drug suppression of ovarian function. Chemotherapy-induced amenorrhea, due to the toxic effect of chemotherapy on the ovaries. Its appearance depends on the age of the patient, and the duration of chemotherapy protocol, as well as the cumulative dose of chemotherapy. Chemotherapy-induced amenorrhea occurs in 70% of premenopausal women, 40% of patients with breast cancer before age 40 years and 90% of women over 40. Several clinical trials show that the occurrence of amenorrhea during chemotherapy in patients with hormone-dependent breast cancer before age 50 improves survival. However, the absence of menstruation due to chemotherapy is not always an indication of adequate suppression of hormone-producing function of the ovaries and / or the onset of menopause. In this revue the main physiological mechanisms of chemotherapy-induced amenorrhea, as well as criteria for the diagnosis and clinical significance of various disorders of ovarian-menstrual cycle in premenopausal patients with breast cancer are discussed.

Ключові слова

breast cancer; chemotherapy-induced amenorrhea; the diagnostic criteria

Повний текст:



Бюлетень Національного канцер-реєстру № 12 "Рак в Україні 2010-2011", Київ, 2013.

Щепотин И.Б., Зотов А.С., Любота Р. В., Аникусько Н. Ф., Любота И. И. Молекулярные типы рака грудной железы, установленные на основе иммуногистохимических маркеров: клинико-биологические особенности и прогноз течения // Клиническая онкология. - 2012. - Т. 4, № 8. - С. 1-4.

Anderson R.A., Cameron D.A. Pretreament serum anti-Mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer // Journal of Clinical Endocrinology and Metabolism. – 2011. – Vol. 96, N 5. – P. 1336-1343. https://doi.org/10.1210/jc.2010-2582

Ben-Aharon I., Bar-Joseph H., Tzarfaty G. et al. Doxorubicin-induced ovarian toxicity // Reproductive Biology and Endocrinology. – 2010. – Vol. 4, N1. – P. 8-20. https://doi.org/10.1186/1477-7827-8-20

Berliere M., Dalenc F., Malingret N. et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracyclin-based chemotherapy with or without docetaxel // BMC Cancer. – 2008. – Vol. 8. – P. 56-62. https://doi.org/10.1186/1471-2407-8-56

Bines J., Oleske D.M., Cobleigh M.A. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer // Journal of Clinical Oncology. – 1998. – Vol. 14, N 5. – P. 1718-1729. https://doi.org/10.1200/jco.1996.14.5.1718

Bonadonna G., Moliterni A., Zambetti M et al. 30 years' follow-up of randomised studies of adjuvant CMF in operable breast cancer // BMJ. – 2005. – Vol. 330, N10. – P. 217-220. https://doi.org/10.1136/bmj.38314.622095.8f

Brougham M.F., Crofton P.M., Johnson E.J. et al. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study // Journal of Clinical Endocrinology and Metabolism. – 2012. – Vol. 97, N 6. – P. 2059-2067. https://doi.org/10.1210/jc.2011-3180

Del Mastro L., Giraudi S., Levaggi A., Pronzato P. Medical approaches to preservation of fertility in female cancer patients // Expert Opinion on Pharmacotherapy. – 2011. – Vol. 12, N3. – P. 387-396. https://doi.org/10.1517/14656566.2011.522568

Devine P.J., Perreault S.D., Luderer U. Roles of reactive oxygen species and antioxidants in ovarian toxicity // Biology of Reproduction. – 2012. – Vol. 86 N2. – P. 1-10. https://doi.org/10.1095/biolreprod.111.095224

De Vos M., Devroey P., Fauser B. Primary ovarian insufficiency // Lancet. – 2010. – Vol. 376. – P. 911-920. https://doi.org/10.1016/s0140-6736(10)60355-8

Domingo J., Guillen V., Ayllon Y. et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment // Fertility and Sterility. – 2012. – Vol. 97, N4. – P. 930-934. https://doi.org/10.1016/j.fertnstert.2012.01.093

Gracia C.R., Sammel M.D., Freeman E.W. et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. // Menopause. – 2005. – Vol. 12, N2. – P. 128-135. https://doi.org/10.1097/00042192-200512020-00005

Goldhirsch A., GelberR., Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: the international breast cancer study group // Ann Oncol. – 1990. – Vol. 9, N1. – P. 183-188.

Goldhirsh A., Wood W.C., Coates A.S. and Panel members. Strategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer // Annals of Oncology. – 2011. – Vol. 22, N8. – P. 1736-1747. https://doi.org/10.1093/annonc/mdr304

Goodwin P.J., Pritchard K.I., Trudeau M., Hood N. Risk of menopause during the first year after breast cancer diagnosis // Journal of Clinical Oncology. – 1999. – Vol. 17, N8. – P. 2365-2370. https://doi.org/10.1200/jco.1999.17.8.2365

Johnson J., Canning J., Kaneko T., Pru J.K., Tilly J.L. Germline stem cells and follicular renewal in the postnatal mammalian ovary // Nature. – 2004. – Vol. 428, N 4. – P. 145-150. https://doi.org/10.1038/nature02316

Kelsey T.W., Wallace W.H. Human ovarian reserve from conception to menopause // PLoS ONE. – 2010. – Vol. 5, N1. – P. 1-9. https://doi.org/10.1371/journal.pone.0008772

La Marca A., Broekmans F.J., Volpe A. et al. Anti-Mullerian hormone (AMH): what do we still need to know? // Human Reproduction. – 2009. – Vol. 24, N9. – P. 2264-2275. https://doi.org/10.1093/humrep/dep210

Lambalk C.B., van Disseldorp J., de Koning C.H., Broekmans F.J. Testing ovarian reserve to predict age at menopause // Maturitas. – 2009. – Vol. 63, N4. – P. 280-291. https://doi.org/10.1016/j.maturitas.2009.06.007

Lee S., Kil W.J., Chun M. et al. Chemotherapy-related amenorrhea in premenopausal women with breast cancer // Menopause. – 2009. – Vol. 16, N1. – P. 98-103. https://doi.org/10.1097/gme.0b013e3181844877

Martin M., Pienkowski T., Mackey J. et al. Adjuvant docetaxel for node-positive breast cancer // N. Engl. J. Med. – 2005. – Vol. 352, N22. – P. 2302-2312. https://doi.org/10.1056/nejmoa043681

Meirow D., Biederman H., Anderson R.A., Wallace W.H. Toxicity of chemotherapy and radiation on female reproduction // Clinical Obstetrics and Gynecology. – 2010. – Vol. 53, N4. – P. 727-739. https://doi.org/10.1097/grf.0b013e3181f96b54

Meirow D., Dor J., Kaufman B. et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury // Human Reproduction. – 2007. – Vol. 22, N2. – P. 1626-1633. https://doi.org/10.1093/humrep/dem027

Meirow D., Lewis H., Nugent D., Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool // Human Reproduction. – 1999. – Vol. 14, N7. – P. 1903-1907. https://doi.org/10.1093/humrep/14.7.1903

National Comprehensive Cancer Network – Breast Cancer Guidelines 2011 // https://www.nccn.org/, accessed June. – 2011.

Oktay K., Oktem O., Reh A., Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer // Journal of Clinical Oncology. – 2006. – Vol. 24, N24. – P. 4044-4046. https://doi.org/10.1200/jco.2006.06.9823

Oktem O., Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function // Cancer. – 2007. – Vol. 110, N10. – P. 2222-2229. https://doi.org/10.1002/cncr.23071

Partridge A., Gelber S., Peppercorn J. et al. Fertility and menopausal outcomes in young breast cancer survivors // Clin Breast Cancer. – 2008. – Vol. 8, N 1. – P. 65-69. https://doi.org/10.3816/cbc.2008.n.004

Partridge A., Ruddy K., Gelber S. et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer // Fertility and Sterility. – 2010. – Vol. 94, N2. – P. 638-644. https://doi.org/10.1016/j.fertnstert.2009.03.045

Pritchard K., Levine M., Bramwell V. et al. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer. update of NCIC CGT MA5 (national cancer institute of Canada clinical trials group trial MA5) // J. Clin. Oncol. – 2005. – Vol. 23, N22. – P. 5166-5170. https://doi.org/10.1200/jco.2005.09.423

Roche H., Fumoleau P., Spielmann M. et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial // J. Clin. Oncol. – 2006. – Vol. 24, N36. – P. 5664-5671. https://doi.org/10.1200/jco.2006.07.3916

Rosendahl M., Andersen C.Y., La Cour Freiesleben N. et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age // Fertility and Sterility. – 2010. – Vol. 94, N1. – P. 156-166. https://doi.org/10.1016/j.fertnstert.2009.02.043

Schover L.R. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility // Journal of Clinical Oncology. – 2008. – Vol. 26, N5. – P. 753-758. https://doi.org/10.1200/jco.2007.14.1655

Sowers M.R., Eyvazzadeh A.D., McConnell D. et al. Anti-Mullerian Hormone and Inhibin B in the Definition of Ovarian Aging and the Menopause Transition // Journal of Clinical Endocrinology and Metabolism. – 2008. – Vol. 93, N9. – P. 3478-3483. https://doi.org/10.1210/jc.2008-0567

Su H. Measuring ovarian function in young cancer survivors // Minerva Endocrinol. – 2010. – Vol. 35, N4. – P. 259-270.

Su H.I., Sammel M.D., Green J. AntiMullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors // Cancer. – 2010. – Vol. 116, N3. – P. 592-599. https://doi.org/10.1002/cncr.24746

Sukumvanich P., Case L.D., van Zee K. et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study // Cancer. – 2010. – Vol. 116, N13. – P. 3102-3111. https://doi.org/10.1002/cncr.25106

Swain S.M., Jeong J.H., Geyer C.E. Jr. et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer // N. Engl. J. Med. – 2010. – Vol. 362, N22. – P. 2053-2065. https://doi.org/10.1056/nejmoa0909638

Tsai-Turton M., Luong B.T., Tan Y., Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion // Toxicological Sciences. – 2007. – Vol. 98, N1. – P. 216-230. https://doi.org/10.1093/toxsci/kfm087

van Disseldorp J., Faddy M.J., Themmen A.P. Relationship of serum antimüllerian hormone concentration to age at menopause // Journal of Clinical Endocrinology and Metabolism. – 2008. – Vol. 93, N6. – P. 2129-2134. https://doi.org/10.1210/jc.2007-2093

van Montfrans J.M., Hoek A., van Hooff M.H. Predictive value of basal follicle-stimulating hormone concentrations in a general subfertility population // Fertility and Sterility. – 2000. – Vol. 74, N1. – P. 97-103. https://doi.org/10.1016/s0015-0282(00)00560-4

Walshe J.M., Denduluri N., Swain S.M. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer // Journal of Clinical Oncology. – 2006. – Vol. 24, N36. – P. 5769-5779. https://doi.org/10.1200/jco.2006.07.2793

Пристатейна бібліографія ГОСТ

DOI: https://doi.org/10.24026/1818-1384.2(43).2013.77474

Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія.

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter